Oral squamous cell carcinomas (OSCC) often develops from oral potentially malignant disorders (OPMDs). Mostly due to late diagnosis, the mortality rate of OSSC has been at 50% for decades. The current standard of care for predicting progression from OPMDs consists of dysplasia grading, which shows highly variable behavior across patients and does not relate very well to the risk of developing cancer from the lesion.

Why Visiopharm’s Discovery software helps
Proteocyte used Visiopharm’s software to develop an APP that detects and quantifies S100A7 in the oral lesion sample.

Download the one-pager